Melatonin releasing PLGA micro/nanoparticles and their effect on osteosarcoma cells

Area of Science:

• Biomaterials Science
• Nanotechnology
• Oncology

Background:

• Osteosarcoma is a primary bone malignancy with limited treatment options.
• Melatonin, a hormone, exhibits potential anti-cancer properties.
• Poly(D,L-lactide-co-glycolide) (PLGA) is a biodegradable polymer widely used in drug delivery systems.

Purpose of the Study:

• To prepare and characterize melatonin-loaded PLGA nanoparticles and microparticles.
• To evaluate the in vitro release kinetics and cellular toxicity of these drug delivery systems.
• To investigate the potential of melatonin-loaded PLGA particles as an adjunct therapy for osteosarcoma.

Main Methods:

• Emulsion-diffusion-evaporation method was used to create PLGA nanoparticles and microparticles.
• Melatonin entrapment efficiency was optimized by adjusting melatonin concentration in the aqueous phase.
• In vitro release studies were conducted over 40 days.
• Cytotoxicity assays were performed on MG-63 osteosarcoma cells using blank and melatonin-loaded PLGA particles.

Main Results:

• Melatonin entrapment efficiency was 14% for nanoparticles and 27% for microparticles.
• Approximately 70% of melatonin was released from both particle types within 40 days, exhibiting a high initial burst release.
• Blank and melatonin-loaded PLGA nanoparticles showed toxic effects on MG-63 cells.
• A significant inhibitory effect of melatonin on MG-63 cells was observed when using microparticles at a specific concentration.

Conclusions:

• Melatonin-loaded PLGA nanoparticles and microparticles can be successfully prepared.
• PLGA polymeric carrier systems show promise for delivering melatonin in osteosarcoma treatment.
• Melatonin, when encapsulated in PLGA carriers, may serve as an effective adjunct to conventional chemotherapy for osteosarcoma.